These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
643 related articles for article (PubMed ID: 30027400)
21. Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Fox D; To TM; Seetasith A; Patel AM; Iannaccone ST Adv Ther; 2023 Mar; 40(3):903-919. PubMed ID: 36534265 [TBL] [Abstract][Full Text] [Related]
22. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice. Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718 [TBL] [Abstract][Full Text] [Related]
23. Nusinersen treatment of spinal muscular atrophy - a systematic review. Albrechtsen SS; Born AP; Boesen MS Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069 [TBL] [Abstract][Full Text] [Related]
24. Discovery of a CNS penetrant small molecule SMN2 splicing modulator with improved tolerability for spinal muscular atrophy. Ando S; Suzuki S; Okubo S; Ohuchi K; Takahashi K; Nakamura S; Shimazawa M; Fuji K; Hara H Sci Rep; 2020 Oct; 10(1):17472. PubMed ID: 33060681 [TBL] [Abstract][Full Text] [Related]
25. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Gidaro T; Servais L Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755 [TBL] [Abstract][Full Text] [Related]
26. Challenges and future perspective of antisense therapy for spinal muscular atrophy: A review. Nakevska Z; Yokota T Eur J Cell Biol; 2023 Jun; 102(2):151326. PubMed ID: 37295266 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992 [TBL] [Abstract][Full Text] [Related]
28. RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides. Torroba B; Macabuag N; Haisma EM; O'Neill A; Herva ME; Redis RS; Templin MV; Black LE; Fischer DF Expert Opin Drug Discov; 2023 Feb; 18(2):181-192. PubMed ID: 36408582 [TBL] [Abstract][Full Text] [Related]
29. Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Michelson D; Ciafaloni E; Ashwal S; Lewis E; Narayanaswami P; Oskoui M; Armstrong MJ Neurology; 2018 Nov; 91(20):923-933. PubMed ID: 30315070 [TBL] [Abstract][Full Text] [Related]
30. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846 [TBL] [Abstract][Full Text] [Related]
31. Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264. Poletti A; Fischbeck KH J Neurochem; 2020 Apr; 153(2):146-149. PubMed ID: 32056234 [TBL] [Abstract][Full Text] [Related]
32. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy. Son HW; Yokota T Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534 [TBL] [Abstract][Full Text] [Related]
33. Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study. Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Bishop KM; Foster R; Liu Y; Ramirez-Schrempp D; Schneider E; Bennett CF; Wong J; Farwell W Lancet Child Adolesc Health; 2021 Jul; 5(7):491-500. PubMed ID: 34089650 [TBL] [Abstract][Full Text] [Related]
34. Nusinersen treatment of Spinal Muscular Atrophy Type 1 - results of expanded access programme in Poland. Modrzejewska S; Kotulska K; Kopyta I; Grędowska E; Emich-Widera E; Tomaszek K; Paprocka J; Chmielewski D; Pilch J; Pietruszewski J; Lemska A; Zawadzka M; Mazurkiewicz-Bełdzińska M Neurol Neurochir Pol; 2021; 55(3):289-294. PubMed ID: 33565602 [TBL] [Abstract][Full Text] [Related]
35. Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease. Rao VK; Kapp D; Schroth M J Manag Care Spec Pharm; 2018 Dec; 24(12-a Suppl):S3-S16. PubMed ID: 30582825 [TBL] [Abstract][Full Text] [Related]
36. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243 [TBL] [Abstract][Full Text] [Related]
37. Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy. Schafernak KT; Jacobsen JR; Hernandez D; Kaye RD; Perez SE Acta Cytol; 2022; 66(1):79-84. PubMed ID: 34515035 [TBL] [Abstract][Full Text] [Related]
38. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA. Leckie J; Yokota T Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532 [TBL] [Abstract][Full Text] [Related]